Browse the evidence

Activation of hepatic AMP-activated protein kinase (AMPK) reduces hepatic glucose production, fatty acid synthesis, and cholesterol synthesis while increasing fatty acid oxidation and mitochondrial biogenesis.

Maintaining energy balance through exercise and dietary patterns that naturally activate AMPK (like fasting or caloric restriction) supports healthy liver metabolism by reducing fat and sugar production while boosting energy burning. Be cautious with unverified supplements claiming to activate AMPK, as their mechanisms may differ from natural physiological activation.

The AMPK activator AICAR has significant off-target effects, including depletion of cellular ATP and inhibition of mitochondrial oxidative phosphorylation, which can confound experimental results.

When interpreting research on AICAR, be aware that it may have off-target effects on mitochondrial function and ATP levels, which could confound results. This is primarily relevant for researchers and those evaluating scientific literature.

Metformin activates hepatic AMPK primarily by inhibiting mitochondrial complex I, leading to reduced ATP and increased AMP, which is distinct from other activators like A-769662.

Metformin works by inhibiting mitochondrial complex I, which lowers ATP and raises AMP, thereby activating AMPK. This mechanism helps reduce hepatic glucose production and improves insulin sensitivity.

Adipose tissue insulin resistance (Adipo-IR) is a primary driver of metabolic and histological abnormalities in obese patients with NAFLD, with worsening Adipo-IR correlating with increased liver fibrosis and hepatic insulin resistance.

For obese individuals with fatty liver, simply having a high BMI is not the only risk factor; the metabolic health of the fat tissue matters significantly. If your fat tissue is insulin resistant, it releases fatty acids that damage the liver. Interventions that improve adipose tissue insulin sensitivity (like weight loss or specific medications like thiazolidinediones) may help reduce liver fibrosis and metabolic risk.

In human skeletal muscle, insulin resistance is caused by a defect in GLUT4 trafficking and translocation, leading to the accumulation of GLUT4 in dense intracellular membrane vesicles rather than its recruitment to the cell surface.

For individuals with insulin resistance, simply having normal levels of glucose transporters (GLUT4) in their muscles is not enough. The problem lies in the cellular machinery's ability to move these transporters to the cell surface in response to insulin. This suggests that interventions must focus on improving cellular signaling and trafficking efficiency, not just increasing transporter abundance.

Conventional dietary-report instruments (FFQs, 24-hour recalls, food records) contain systematic measurement errors that invalidate their use as reference standards for adjusting nutritional epidemiology data, leading to severe underestimation of diet-disease associations.

If you are reading nutritional studies that rely on self-reported food diaries or questionnaires to determine health risks, be aware that these studies likely underestimate the true strength of the relationship between diet and disease. The tools used to measure what people eat are flawed in predictable ways, often masking real health benefits or risks. Do not assume a 'no association' finding means there is no link; it may simply mean the measurement tool was too noisy to detect it.

Short-term satiety signals (like CCK and glucose) are insufficient to regulate long-term body adiposity and can be overridden by long-term regulators (insulin and leptin).

Feeling full from a meal doesn't guarantee you won't gain weight long-term. Your body uses long-term hormones like leptin and insulin to set your 'weight thermostat.' If your diet disrupts these hormones, you might feel full but still gain weight because your brain isn't getting the long-term signal that you have enough energy stores.

Global dietary calcium and zinc deficiency risks are decreasing but remain highly prevalent, with 3.5 billion and 1.1 billion people at risk respectively in 2011, primarily in Africa and Asia.

Global food systems are currently failing to provide adequate calcium and zinc for billions, particularly in Africa and Asia. While risks are decreasing, they remain high. Individual efforts are insufficient; systemic changes like crop breeding and fortification are necessary.

In adolescent girls with PCOS, hyperandrogenemia (specifically elevated bioavailable testosterone) is an independent risk factor for metabolic syndrome, increasing the odds of MBS by approximately 4-fold per quartile of testosterone after adjusting for obesity and insulin resistance.

For adolescent girls with PCOS, high testosterone levels are a direct driver of metabolic syndrome risk, separate from how much they weigh. This means that even if a patient is not obese, high androgens can still put them at risk for metabolic issues. Treatment strategies should consider targeting androgen levels, not just weight.

Chronic nutrient excess and obesity overwhelm adipose tissue storage capacity, causing ectopic lipid accumulation in liver and muscle, which triggers lipotoxicity and metaflammation, leading to insulin resistance and metabolic disease.

When you consistently consume more energy than your body can store in fat tissue, the excess fat spills over into organs like the liver and muscles. This spillage is toxic and triggers inflammation that blocks insulin, leading to type 2 diabetes. Managing nutrient intake to stay within your body's storage capacity is key to preventing this cascade.

Saturated fatty acids (e.g., palmitate) and oxidized cholesterol drive metaflammation by activating stress kinases (JNK, PKC, PKR) and inflammatory pathways (TLR4, NF-kB), which directly inhibit insulin signaling.

High intake of saturated fats and oxidized lipids can directly interfere with how your cells respond to insulin by triggering inflammatory stress signals. Reducing these specific lipid types may help maintain insulin sensitivity.

Obesity causes hypertension through multiple mechanisms including sympathetic nervous system activation, renin-angiotensin system (RAS) overexpression in adipose tissue, and renal sodium retention.

If you have obesity, your risk for high blood pressure is significantly increased due to biological mechanisms involving your nervous system and hormones. Managing your weight through diet and exercise can help mitigate these risks.

SIRT3 is required for the full activation of AMPK and CREB, and the subsequent upregulation of PGC-1α expression in skeletal muscle.

SIRT3 acts as an upstream activator for other key metabolic regulators like AMPK and PGC-1α. Without sufficient SIRT3, the muscle's ability to activate these energy-sensing and mitochondrial-building pathways is significantly reduced.

Obese individuals have attenuated postprandial secretion of satiation signals like PYY and GLP-1 compared to lean individuals, which may contribute to obesity.

If you are obese, your body may naturally produce less of the 'fullness' hormones (like PYY) after eating compared to lean people. This is a biological factor, not just a lack of willpower.

In healthy elderly individuals, the combination of amino acids and glucose-induced hyperinsulinemia fails to stimulate muscle protein synthesis, resulting in a blunted anabolic response compared to young adults.

For older adults, consuming protein alongside carbohydrates (like in typical mixed meals or standard supplements) may not build muscle because the insulin response blocks the muscle-building signal. To potentially maximize muscle protein synthesis, older adults might benefit from consuming amino acids or protein without concurrent carbohydrate intake, as the addition of glucose appears to blunt the anabolic response in aging muscle.

Metformin activates AMPK indirectly by inhibiting mitochondrial Complex I, leading to increased AMP/ADP ratios, but its primary therapeutic benefit in lowering hepatic glucose production is mediated by AMPK-independent mechanisms involving adenylate cyclase inhibition.

Metformin is a first-line treatment for type 2 diabetes. While it does activate energy-sensing pathways (AMPK), its ability to lower blood sugar in the liver also works through other mechanisms involving cellular energy levels. This complexity does not diminish its status as a standard, effective therapy.

Insulin resistance and compensatory hyperinsulinemia drive hyperandrogenemia in PCOS by disrupting the hypothalamus-hypophysis-ovary axis and directly stimulating ovarian steroidogenesis, creating a self-perpetuating vicious cycle.

For women with PCOS, managing insulin resistance is likely more critical for symptom control than focusing solely on reproductive aspects. Strategies that improve insulin sensitivity (such as dietary changes or specific medications like metformin, though not detailed here) may help reduce androgen levels and improve ovarian function.

Central insulin resistance is a common pathophysiological mechanism linking Type 2 Diabetes and Alzheimer's Disease, contributing to cognitive decline and metabolic dysregulation.

If you have Type 2 Diabetes, managing your blood sugar is also about protecting your brain. Central insulin resistance is a key link between diabetes and cognitive decline (like Alzheimer's). Prioritizing insulin sensitivity through lifestyle or medication may help preserve cognitive function, as the brain relies on proper insulin signaling for memory and metabolic health.

Insulin crosses the blood-brain barrier via a saturable transport system, and this transport is impaired in conditions like obesity, diabetes, and aging.

High peripheral insulin levels (common in obesity and diabetes) may not effectively reach the brain due to a saturated transport system. This 'central insulin resistance' can occur even if peripheral insulin is high, potentially contributing to metabolic and cognitive issues.

Insulin in the brain acts as an anorexigenic hormone, regulating food intake and energy expenditure through hypothalamic receptors, distinct from its peripheral anabolic effects.

Insulin in the brain helps regulate hunger. Disruptions in this central signaling (central insulin resistance) may contribute to overeating and obesity. Restoring healthy insulin signaling in the brain could theoretically support better appetite regulation.

Continuous positive airway pressure (CPAP) therapy effectively reverses sleep-related disordered breathing and daytime symptoms, and mitigates acute pathophysiologic responses such as sympathetic activation and endothelin elevation, though long-term cardiovascular mortality benefits remain unproven.

If you have been diagnosed with Obstructive Sleep Apnea, CPAP is the most effective treatment to stop breathing interruptions and reduce daytime sleepiness. While it may not yet be proven to extend life expectancy in heart failure patients, it significantly improves cardiovascular markers like blood pressure and sympathetic activity. If you struggle with the mask, ask your provider about heated humidification or nasal sprays to improve comfort and adherence.

Laboratory values (e.g., albumin, prealbumin) are poor standalone indicators of nutritional status due to their sensitivity to inflammation and other non-nutritional factors, and should be interpreted within the clinical context.

Do not use albumin or prealbumin levels alone to diagnose malnutrition, especially in acutely ill or inflamed patients. These markers are influenced by disease state and inflammation. Use them as part of a broader assessment including clinical history, physical exam, and functional measures.

The nuclear receptor NR4A3 is a critical regulator of exercise-induced metabolic responses, including glucose uptake and mitochondrial function, as its silencing ablates these benefits in human muscle cells.

NR4A3 is a key gene that helps muscles respond to exercise by improving glucose uptake and mitochondrial function. While you cannot directly 'dose' this gene, regular exercise upregulates it, thereby enhancing metabolic health.

Adiponectin and members of the TGF-beta superfamily (such as BMP7 and Activin B) regulate adipocyte differentiation, mitochondrial biogenesis, and energy expenditure, serving as potential pharmacotherapeutic targets for obesity.

Hormones like adiponectin and growth factors like BMP7 play key roles in regulating fat storage and energy expenditure. Research into these pathways may lead to new treatments for obesity and diabetes.